financetom
Business
financetom
/
Business
/
Mexican cement maker Cemex ekes out profit, starts $350 million savings program
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mexican cement maker Cemex ekes out profit, starts $350 million savings program
Feb 6, 2025 3:30 AM

MEXICO CITY, Feb 6 (Reuters) - Mexico's Cemex

posted a net profit in the fourth quarter on

Thursday, as price hikes helped offset a drop in sales, while

the cement maker also rolled out a savings program aimed at

delivering a $350 million earnings boost by 2027.

Cemex's net profit in the quarter reached $48.31 million,

but missed the estimate of $91.29 million from analysts polled

by LSEG, as sales were down 5% year-on-year at $3.81 billion.

The cement and concrete maker's volumes were down in nearly

all sectors, with Cemex citing lower demand in its key markets,

Mexico and the United States.

Volumes in Mexico dropped following the country's mid-year

elections, Cemex said. In the U.S., operations were hit by a

series of hurricanes and a freeze in Texas, which dinged its

core earnings by some $38 million, according to the company.

Cemex said it is optimistic about this year's volumes in the

U.S. on infrastructure and manufacturing projects, while Mexico

will likely continue to face headwinds in the first half.

In a statement accompanying its earnings report, Cemex

announced the launch of a cost-cutting program designed to add

$350 million to its core earnings by 2027.

The company plans to achieve this by streamlining

operations, improving efficiency and leveraging digital

technology, although it did not provide further details.

The program is expected to contribute $150 million to

earnings this year, with further increases thereafter, while

also delivering savings to the free cash flow line, according to

the company.

Starting this year, Cemex will invest in "growth through

small- to medium-sized acquisitions, primarily in the U.S.,

additional deleveraging and building further on (its)

shareholder return programs," CEO Fernando Gonzalez said.

Cemex has exited a number of non-core businesses to shift

its focus toward the U.S. market. Last year, it sold off its

operations in the Philippines, Guatemala and the Dominican

Republic.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Nov 15, 2024
(Reuters) - U.S. farmers struggling with slumping incomes and depressed grain prices have been switching to cheaper generic pesticides and fungicides as they plan for spring planting next year, which market analysts said could hit the bottom lines of agrichemical companies like Bayer. Signs of these financial impacts are already emerging. Bayer shares fell sharply to a 20-year low on...
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
Nov 15, 2024
07:03 AM EST, 11/14/2024 (MT Newswires) -- AtkinsRealis ( SNCAF ) on Thursday said third-quarter adjusted profit and revenue rose. The engineering services and nuclear company said adjusted profit attributable to shareholders from professional services and project management (PS&PM) increased 64% to $110.1 million, or $0.63 per diluted share, from $67.3 million, or $0.38 per diluted share, last year. Services...
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
Nov 15, 2024
07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results. The trial met its key secondary endpoint of overall...
Market Chatter: Spotify to Begin Paying Video Podcasters
Market Chatter: Spotify to Begin Paying Video Podcasters
Nov 15, 2024
07:03 AM EST, 11/14/2024 (MT Newswires) -- Spotify Technology ( SPOT ) plans to start paying makers of popular video podcasts to appear on its platform, Bloomberg reported Wednesday, citing Spotify's ( SPOT ) chief executive officer, Daniel Ek. It will also soon offer its paid subscribers ways to watch without ads, the report said. Spotify ( SPOT ) seeks...
Copyright 2023-2026 - www.financetom.com All Rights Reserved